Heterogeneous multi-compartmental DNA hydrogel particles prepared via microfluidic assembly for lymphocyte-inspired precision medicine
Source abstract
Abstract
Lymphocytes play a vital role in immunosurveillance through sensing biomolecules and eliminating targeted invaders. Compared with conventional therapies that depend on drug loading, lymphocytes are advantageous as they are able to ensure self-regulated therapeutics. Here, novel multi-compartmental DNA hydrogel particles were synthesized using a microfluidic assembly for intelligent cancer treatment via the logic-based control of siRNA release without external stimulation. The sensing sequence (D1) was compartmentalized from the treatment sequence (D2) with the use of core-shell DNA hydrogel particles. When D1 detects a cancer-associated biomarker, miRNA-21, a sequence cascade is triggered to release siRNA from D2, effectively eliminating the targeted cancer cells via lymphocyte-inspired precision medicine.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · CAR-T cell therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedical Engineering, National University of Singapore, 4 Engineering Drive 3, 04-08, 117583, Singapore
Institute for Health Innovation and Technology (iHealthtech), MD6, 14 Medical Drive #14-01, Singapore 117599
Department of Biomedical Engineering, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon, Hong Kong, China
Funding
City University of Hong Kong · National Research Foundation Singapore · National Medical Research Council · Ministry of Education - Singapore · National Natural Science Foundation of China
References (42)
Show source-provided references
1. Yuen · Trends Cancer · 2016 · 2 · 74710.1016/j.trecan.2016.10.010 ↗
2. Hamaï · Tissue Antigens · 2010 · 75 · 110.1111/j.1399-0039.2009.01401.x ↗
3. Rohaan · Virchows Arch. · 2019 · 474 · 44910.1007/s00428-018-2484-0 ↗
4. June · Nat. Med. · 2017 · 23 · 54010.1038/nm.4321 ↗
5. Davila · Sci. Transl. Med. · 2014 · 6 · 224ra2510.1126/scitranslmed.3008226 ↗
6. Sterner · Blood Cancer J. · 2021 · 11 · 110.1038/s41408-021-00459-7 ↗
7. Abreu · J. Controlled Release · 2020 · 319 · 24610.1016/j.jconrel.2019.12.047 ↗
8. Pons-Faudoa · Biomed. Microdevices · 2019 · 21 · 4710.1007/s10544-019-0389-6 ↗
9. Li · Nat. Rev. Mater. · 2016 · 1 · 1
10. Zhang · Nat. Commun. · 2019 · 10 · 110.1038/s41467-018-07882-8 ↗
11. Luo · Chem. Commun. · 2013 · 49 · 788710.1039/c3cc44111c ↗
12. Buenger · Prog. Polym. Sci. · 2012 · 37 · 167810.1016/j.progpolymsci.2012.09.001 ↗
13. Wang · Pharmacol. Res. · 2010 · 62 · 9010.1016/j.phrs.2010.03.005 ↗
14. Yhee · Nanoscale · 2014 · 6 · 1338310.1039/C4NR04334K ↗
15. Kanasty · Nat. Mater. · 2013 · 12 · 96710.1038/nmat3765 ↗
16. Hannon · Nature · 2002 · 418 · 24410.1038/418244a ↗
17. Bobbin · Annu. Rev. Pharmacol. Toxicol. · 2016 · 56 · 10310.1146/annurev-pharmtox-010715-103633 ↗
18. Levanova · Front. Microbiol. · 2018 · 9 · 215110.3389/fmicb.2018.02151 ↗
19. Petrocca · J. Clin. Oncol. · 2011 · 29 · 74710.1200/JCO.2009.27.6287 ↗
20. Shen · Cancer Gene Ther. · 2012 · 19 · 36710.1038/cgt.2012.22 ↗
21. Martina · Biomaterials · 2007 · 28 · 414310.1016/j.biomaterials.2007.05.025 ↗
22. Wang · J. Controlled Release · 2018 · 285 · 15210.1016/j.jconrel.2018.07.004 ↗
23. Wang · VIEW · 2021 · 2 · e14610.1002/viw2.146 ↗
24. Hu · J. Am. Chem. Soc. · 2010 · 132 · 1147010.1021/ja105616v ↗
25. Schoonen · Adv. Mater. · 2016 · 28 · 110910.1002/adma.201502389 ↗
26. Yang · J. Am. Chem. Soc. · 2015 · 137 · 136210.1021/ja512337z ↗
27. Le Goff · Eur. Polym. J. · 2015 · 72 · 38610.1016/j.eurpolymj.2015.02.022 ↗
28. Chen · Trends Cell Biol. · 2012 · 22 · 66210.1016/j.tcb.2012.07.002 ↗
29. Elani · Nat. Commun. · 2014 · 5 · 110.1038/ncomms6305 ↗
30. Guiseppi-Elie · Adv. Mater. · 2002 · 14 · 74310.1002/1521-4095(20020517)14:10<743::AID-ADMA743>3.0.CO;2-H ↗
31. He · ACS Appl. Mater. Interfaces · 2016 · 8 · 874310.1021/acsami.6b01278 ↗
32. Tan · Nat. Commun. · 2017 · 8 · 66310.1038/s41467-017-00757-4 ↗
33. Xu · RSC Adv. · 2016 · 6 · 4362610.1039/C6RA03620A ↗
34. Reid · J. Tissue Eng. Regener. Med. · 2015 · 9 · 31510.1002/term.1688 ↗
35. Lei · Acta Biomaterialia · 2017 · 55 · 39610.1016/j.actbio.2017.03.042 ↗
36. Kelmansky · Mol. Pharmaceutics · 2017 · 14 · 360910.1021/acs.molpharmaceut.7b00736 ↗
37. Patutina · Front. Pharmacol. · 2019 · 10 · 87910.3389/fphar.2019.00879 ↗
38. Bautista-Sánchez · Mol. Ther.–Nucleic Acids · 2020 · 20 · 40910.1016/j.omtn.2020.03.003 ↗
39. Liu · Int. J. Anal. Chem. · 2018 · 3625823
40. Wu · Cell. Physiol. Biochem. · 2017 · 43 · 94510.1159/000481648 ↗
41. Liu · Cancer Gene Ther. · 2021 · 2021 · 110.1038/s41417-020-0200-0 ↗
42. Papke · ACS Pharmacol. Transl. Sci. · 2021 · 4 · 70310.1021/acsptsci.0c00165 ↗